Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDRX Biodexa Pharmaceuticals	$0.93 +1.9%	$1.22	$0.78 ▼ $41.50	$33.26M	1.21	1.09 million shs	276,431 shs
MDCX Medicus Pharma	$3.10 +13.6%	$4.15	$1.80 ▼ $8.94	$37.05M	N/A	386,620 shs	538,971 shs
RNTX Rein Therapeutics	$1.45 -5.8%	$1.86	$1.35 ▼ $4.40	$34.12M	1.3	24,242 shs	40,943 shs
TRAW Traws Pharma	$1.43 +0.7%	$1.50	$0.97 ▼ $19.44	$7.90M	1.48	446,007 shs	89,388 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDRX Biodexa Pharmaceuticals	+1.93%	-9.94%	-19.34%	-24.59%	+92,759,900.00%
MDCX Medicus Pharma	+13.55%	+20.16%	-49.68%	-0.96%	+309,999,900.00%
RNTX Rein Therapeutics	-5.84%	-11.59%	-27.50%	-14.71%	+144,999,900.00%
TRAW Traws Pharma	+0.70%	-13.33%	+2.14%	-40.42%	+142,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BDRX Biodexa Pharmaceuticals	0.1944 of 5 stars	0.0	3.0	0.0	0.0	1.8	0.0	0.0
MDCX Medicus Pharma	1.89 of 5 stars	3.8	0.0	0.0	0.0	2.5	0.8	0.0
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TRAW Traws Pharma	0.3045 of 5 stars	0.0	3.0	0.0	0.0	1.9	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BDRX Biodexa Pharmaceuticals	0.00	N/A	N/A	N/A
MDCX Medicus Pharma	3.50	Strong Buy	$23.50	658.06% Upside
RNTX Rein Therapeutics	0.00	N/A	N/A	N/A
TRAW Traws Pharma	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest TRAW, BDRX, MDCX, and RNTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/23/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
6/9/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
5/29/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00
5/22/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$27.00 ➝ $27.00
5/12/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$14.00 ➝ $27.00
5/8/2025	MDCX Medicus Pharma	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $20.00
4/28/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/21/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $14.00
4/14/2025	MDCX Medicus Pharma	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/14/2025	MDCX Medicus Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BDRX Biodexa Pharmaceuticals	$470K	72.12	N/A	N/A	$0.29 per share	3.20
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	$0.29 per share	N/A
RNTX Rein Therapeutics	N/A	N/A	$0.42 per share	3.44	$0.43 per share	N/A
TRAW Traws Pharma	$230K	34.57	N/A	N/A	($8.66) per share	-0.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BDRX Biodexa Pharmaceuticals	-$7.32M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	7/11/2025 (Estimated)
MDCX Medicus Pharma	-$11.16M	-$1.16	N/A	N/A	N/A	N/A	-380.03%	-224.22%	6/27/2025 (Estimated)
RNTX Rein Therapeutics	-$62.88M	-$2.86	N/A	N/A	N/A	N/A	-86.07%	-31.11%	N/A
TRAW Traws Pharma	-$166.52M	-$32.81	N/A	N/A	N/A	-15,245.81%	N/A	-193.21%	8/13/2025 (Estimated)

Latest TRAW, BDRX, MDCX, and RNTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	RNTX Rein Therapeutics	-$0.21	-$0.25	-$0.04	-$0.25	N/A	N/A
5/15/2025	Q1 2025	TRAW Traws Pharma	-$8.04	$2.09	+$10.13	$2.09	$0.06 million	$0.06 million
5/12/2025	Q1 2025	MDCX Medicus Pharma	-$0.23	-$0.42	-$0.19	-$0.42	N/A	N/A
4/7/2025	Q4 2024	RNTX Rein Therapeutics	N/A	-$0.26	N/A	-$1.89	N/A	N/A
3/31/2025	Q4 2024 & Study Update	TRAW Traws Pharma	-$7.00	$95.66	+$102.66	$95.66	$0.06 million	$0.06 million
3/28/2025	Q4 2024	MDCX Medicus Pharma	-$0.32	-$0.18	+$0.14	-$0.18	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BDRX Biodexa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MDCX Medicus Pharma	N/A	N/A	N/A	N/A	N/A
RNTX Rein Therapeutics	N/A	N/A	N/A	N/A	N/A
TRAW Traws Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BDRX Biodexa Pharmaceuticals	0.01	1.75	1.75
MDCX Medicus Pharma	N/A	1.53	1.53
RNTX Rein Therapeutics	N/A	1.39	1.39
TRAW Traws Pharma	N/A	1.81	1.81

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BDRX Biodexa Pharmaceuticals	17.51%
MDCX Medicus Pharma	N/A
RNTX Rein Therapeutics	90.89%
TRAW Traws Pharma	7.95%

Insider Ownership

Company	Insider Ownership
BDRX Biodexa Pharmaceuticals	0.34%
MDCX Medicus Pharma	N/A
RNTX Rein Therapeutics	5.10%
TRAW Traws Pharma	13.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BDRX Biodexa Pharmaceuticals	20	36.54 million	36.42 million	Not Optionable
MDCX Medicus Pharma	N/A	13.57 million	N/A	N/A
RNTX Rein Therapeutics	9	22.15 million	21.02 million	N/A
TRAW Traws Pharma	17	5.56 million	4.81 million	Optionable

TRAW, BDRX, MDCX, and RNTX Headlines

Recent News About These Companies

Traws Pharma Announces Promising Clinical Data for Rigosertib in Rare Cancer

June 5, 2025 | msn.com

Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib

June 3, 2025 | globenewswire.com

Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness

May 27, 2025 | globenewswire.com

Traws Pharma Unveils New Strategic Antiviral Focus

May 19, 2025 | tipranks.com

Traws Pharma Highlights Q1 2025 Financial Progress and Antiviral Developments

May 18, 2025 | msn.com

Traws Pharma Reports First Quarter 2025 Results and Business Highlights

May 15, 2025 | globenewswire.com

Traws Pharma Appoints New Chairman Amid Leadership Changes

April 18, 2025 | tipranks.com

The Escalator: HHS, Spectrum Science, Alvotech and more

April 3, 2025 | mmm-online.comM

Traws Pharma Reports 2024 Financial Results and Advances Bird Flu and COVID Programs

April 2, 2025 | msn.com

Traws Pharma reports FY24 EPS ($35.21)

April 1, 2025 | markets.businessinsider.com

Traws Pharma, Inc. (TRAW) Virtual Investor Event Transcript

April 1, 2025 | seekingalpha.com

Traws Pharma, Inc.: Traws Pharma Reports Full Year 2024 Results and Business Highlights

March 31, 2025 | finanznachrichten.de

Traws Pharma Reports Full Year 2024 Results and Business Highlights

March 31, 2025 | markets.businessinsider.com

Traws Pharma Announces CEO Transition as Werner Cautreels Retires

March 30, 2025 | msn.com

Traws Pharma, Inc.: Traws Pharma Announces Management Updates

March 29, 2025 | finanznachrichten.de

Traws Pharma: Werner Cautreels to Retire as CEO, While Continuing as a Bd Member >TRAW

March 29, 2025 | marketwatch.com

Traws Pharma: Werner Cautreels to Retire as CEO, While Continuing as a Bd Member >TRAW

March 29, 2025 | marketwatch.com

Traws Pharma Announces Virtual Investor Event to Showcase Innovative Treatments for Bird Flu and COVID-19

March 29, 2025 | msn.com

Traws Pharma CEO Werner Cautreels retires, Iain Dukes named interim CEO

March 29, 2025 | markets.businessinsider.com

Traws Pharma Announces Management Updates

March 28, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRAW, BDRX, MDCX, and RNTX Company Descriptions

Biodexa Pharmaceuticals NASDAQ:BDRX

$0.93 +0.02 (+1.93%)

Closing price 06/26/2025 03:59 PM Eastern

Extended Trading

$0.91 -0.02 (-1.90%)

As of 08:15 AM Eastern

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Medicus Pharma NASDAQ:MDCX

$3.10 +0.37 (+13.55%)

As of 06/26/2025 04:00 PM Eastern

Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.

Rein Therapeutics NASDAQ:RNTX

$1.45 -0.09 (-5.84%)

As of 06/26/2025 04:00 PM Eastern

Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

Traws Pharma NASDAQ:TRAW

$1.43 +0.01 (+0.70%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$1.51 +0.08 (+5.59%)

As of 08:00 AM Eastern

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time